Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumati Gupta

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
The Journal of Nutrition|May 21, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
International Journal of Molecular Sciences|January 25, 2025
Clinical and Genomic Features of Androgen Indifferent Prostate CancerJack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, et al.
Clinical Genitourinary Cancer|November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaYung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
European Urology|August 28, 2020
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial CarcinomaYung Lyou, Petros Grivas, Jonathan E Rosenberg, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
The Journal of Nutrition|May 21, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
International Journal of Molecular Sciences|January 25, 2025
Clinical and Genomic Features of Androgen Indifferent Prostate CancerJack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, et al.
Clinical Genitourinary Cancer|November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial CarcinomaYung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
European Urology|August 28, 2020
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial CarcinomaYung Lyou, Petros Grivas, Jonathan E Rosenberg, et al.
Pageof 7